Q1 2025 Management View CEO Brian Lian highlighted the company's progress in advancing its VK2735 obesity program, with Phase ...

Viking plans to explore monthly dosing for ... for weight loss in the ongoing VENTURE trial for oral VK2735. Brian Lian ...

interest in participating in the Phase 2 VENTURE-Oral study was high and drove an efficient rate of enrollment," said Brian Lian, Ph.D., chief executive officer of Viking Therapeutics.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian ...